Radiation Safety at the Time of Patient Discharge in Persons Undergoing Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging
Öz
Aim: F-18 FDG (fluorodeoxyglucose) PET/CT is an imaging method increasingly used in nuclear medicine due to the rising incidence of cancer in society. Additionally, since this imaging is performed with higher photon energy, it significantly increases anxiety among hospital staff. In our study, we aimed to measure the radiation dose rate ratio released to the environment and evaluate environmental radiation exposure in patients who underwent PET/CT with F-18 fluorodeoxyglucose (FDG) at the time of discharge.
Materials and Methods: Dose rates at 0.5 meters (m), 1 m, and 2 m from the anterior chest of 123 patients (M/F: 69/54) who underwent F-18 FDG PET/CT imaging in the Department of Nuclear Medicine PET/CT were measured using a survey meter.
Findings: Patients received an average of 8.05 mCi (millicurie) of radioactive material and waited in the clinic for 78.34 minutes. Following the imaging, the average radiation dose rates at 0.5 m, 1 m, and 2 m were found to be 11.33 ± 2.67, 5.7 ± 1.3, and 2.3 ± 5 µSv/h, respectively (Tables 1, 2, 3) (Figure 1). There was a statistically significant (p < 0.0001) negative correlation between the duration of hospital stay after F-18 FDG injection and the F-18 FDG dose injected into the patient and the dose rates measured at all three distances. (Table 4, 5) (Figure 1).
Conclusion: Our study showed that the F-18 FDG PET/CT scans done in the Nuclear Medicine Department were for diagnostic purposes. This means that, according to international and national radiation safety rules, the department is exposed to low doses and does not pose a threat to the environmental radiation safety. Additionally, the staff member or caregiver receives a significantly lower dose as they are farther from the patient.
Anahtar Kelimeler
Kaynakça
- 1.Phillips EH, Iype R, Wirth A. PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Br J Radiol. 2021;94:20210576.
- 2.Haidar M, Rizkallah J, El Sardouk O, El Ghawi N, Omran N, Hammoud Z, et al. Radiotracer Innovations in Breast Cancer Imaging: A Review of Recent Progress. Diagnostics (Basel). 2024;14:1943.
- 3.Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-54.
- 4.Leide-Svegborn S. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosimetry. 2010;139:208-13.
- 5.Parlak Y, Uysal B, Kıraç FS, Kovan B, Demir M, Ayan A, et al. Radyasyon Güvenliği Kılavuzu: Genel Tanımlar ve Nükleer Tıp Uygulamalarında Radyasyondan Korunma Kuralları. Nucl Med Semin. 2020;6:71-89.
- 6.European Commission. Radiation Protection 97: Radiation Protection Following Iodine-131 Therapy (Exposure due to out-patients or discharged inpatients). Luxembourg, Belgium: Office for Official Publications of the European Communities; 1998.
- 7.Radyasyon Güvenliği Yönetmeliği, 24.3.2000. Resmî Gazete (Sayı: 23999). Erişim adresi: https://www.resmigazete.gov.tr/arsiv/23999.pdf
- 8.Yeyin N, Abuqbeıtah M, Çavdar İ, Sönmezoğlu K, Demir M. The Evaluation of Dose Rate Measurements and Patients Discharge In Radionuclide Therapy. İst Tıp Fak Derg. 2017;80:1-6.
- 9.Roberts FO, Gunawardana DH, Pathmaraj K, Wallace A, U PL, Mi T, et al. Radiation dose to PET technologists and strategies to lower occupational exposure. J Nucl Med Technol. 2005;33:44-7.
- 10.Valentin J. Radiation dose to patients from radiopharmaceuticals: (Addendum 2 to ICRP Publication 53) ICRP Publication 80 Approved by the Commission in September 1997. Annals of the ICRP. 1998;28:1-126.